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ABSTRACT
Background Non-small cell lung cancer (NSCLC)
comprises approximately 85% of all lung cancer cases,
and surgery is the preferred treatment for patients. The
National Health Service established Primary Care Trusts
(PCTs) in 2002 to manage local health needs. We
investigate whether PCTs with a lower uptake of surgical
treatment are those with above-average mortality 1 year
after diagnosis. The applied methods can be used to
monitor the performance of any administrative bodies
responsible for the management of patients with cancer.
Methods All adults diagnosed with NSCLC lung cancer
during 1998–2006 in England were identiﬁed. We ﬁtted
mixed effect logistic models to predict surgical treatment
within 6 months after diagnosis, and mortality within
1 year of diagnosis.
Results Around 10% of the NCSLC patients received
curative surgery. Older deprived patients and those who
did not receive surgery had much higher odds of death
1 year after being diagnosed with cancer. In total, 69%
of the PCTs were below the lower control limit of
surgery and have predicted random intercepts above the
mean value of zero of the random effect for mortality,
whereas 40% were above the upper control limit of
mortality within 1 year.
Conclusions Our main results suggest the presence of
clear geographical variation in the use of surgical
treatment of NSCLC and mortality. Mixed-effects models
combined with the funnel plot approach were useful for
assessing the performance of PCTs that were above
average in mortality and below average in surgery.
INTRODUCTION
Lung cancer is the most common cancer diagnosed
in the world and is responsible for a quarter of
male cancer deaths and one-ﬁfth of female cancer
deaths. A total of 1.8 million cases were diagnosed
in 2012, accounting for around 13% of all new
cancer cases.1 In 2011 in the UK, lung cancer was
the second most common cancer in men (23 770
new cases) and women (19 693 new cases),
accounting for 14% of all cancer cases in men and
11% in women.2 There has been a steady decline
in the number of incidence cases in men and a
modest increase in the number of cases in women
in the past 30 years in the UK and many other
countries worldwide.
Lung cancer is divided into two main groups:
small cell lung cancer (SCLC) and non-small cell
lung cancer (NSCLC). The latter comprises
approximately 85% of all lung cancer cases. The
most common types of NSCLCs are adenocarcin-
oma, squamous cell carcinoma and large cell car-
cinoma. Surgery is the preferred treatment for
patients with early-stage NSCLC providing the
greatest chance of long-term survival in such
patients. The overall proportion of all patients with
lung cancer undergoing surgical resection in
England between 2004 and 2006 was less than
10%, with older patients having the lowest likeli-
hood of resection,3 though the number of resec-
tions has been increasing in recent years.4 A UK
hospital recently reported a resection rate of 25%,
which is comparable with the European standard,5
and the annual report of the English National Lung
Cancer Audit (NLCA) reporting data on patients
ﬁrst diagnosed in 2012 (National Lung Cancer
Audit 2013) reported a resection rate of 22% in
patients with biopsy-conﬁrmed NSCLC. However,
in that report, the NLCA also demonstrated that
even in patients with stages I and II NSCLCs, the
resection rate varied by region (Cancer Networks)
from 32% to 65%. Surgical treatment in patients
with NSCLC decreases considerably with the age
of the patient at diagnosis,4 6 while outcomes of
treatment of patients diagnosed at an older age are
very similar to those of younger patients.7
Survival from lung cancer has remained poor in
England, and although there have been recent
improvements in 1-year survival rates,8 9 there has
only been very slight improvement in 5-year sur-
vival in the past decade;10 5-year survival was
found to be among the lowest of six worldwide
countries with comparable wealth.11 Persistent geo-
graphic inequalities in cancer survival are also seen
within the UK, with a clear north-south gradient
when survival between Primary Care Trusts (PCTs)
was compared over time12 13 and for cancer
networks.14 15
The National Health Service (NHS) Cancer
Plan16 set out a national programme, the aim of
which was to improve cancer outcomes by improv-
ing early diagnosis, screening and access to treat-
ment for all patients with cancer. Extra funding
was released, with the actual expenditure on cancer
reaching £636 million in 2003–2004. The NHS
established PCTs in 2002 to manage local health
needs, subject to national standards and guidance.
In April 2013, the 151 PCTs that were responsible
for the management of 80% of the NHS budget
were replaced with clinical commissioning groups
(CCGs) numbering 211 at the time of writing. The
health-related outcome of patients living in the
same geographical area which falls under the man-
agement of the same PCT may be more similar to
each other than those of patients from different
areas. They are more likely to share similar social
and lifestyle characteristics and healthcare facilities.
There was also concern at that time that not all of
the funding allocated by the NHS for cancer was in
fact spent on cancer services, and therefore in 2004
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PCTs were asked to report the proportion of their budget spent
on major diseases such as cancer. The King’s Fund released a
report in 2006 showing signiﬁcant variation in budgets for
cancer reported by PCTs.17
Socioeconomic disparities have been shown in lung cancer sur-
vival for both sexes, with lower survival among deprived
groups.18–20 A study of the survival of patients with lung cancer
in Scotland found that although deprived patients had the same
chance of receiving curative treatment, they were less likely to
survive 3 years after diagnosis than afﬂuent patients.21
Inequalities were also observed in access to treatment and sur-
vival in 26 health authorities in South East England.22 Higher
overall treatment rates in the Yorkshire region of England have
been shown to be associated with better survival rates.23
The main aim of this study is to investigate whether PCTs with
a lower uptake of surgical treatment are those with above-average
mortality 1 year after diagnosis, and to assess the impact of
known factors inﬂuencing these two outcomes, such as age at
diagnosis, socioeconomic deprivation, sex and PCT spending on
lung cancer. With continuous change in the size and geographical
boundaries of administrative bodies responsible for the manage-
ment, planning and funding of healthcare in England, we believe
that the methods described here can be used to monitor and
compare the performance and outcomes of all administrative
bodies, irrespective of their size and number.
METHODS
Data
All adults within the age range 15–99 years diagnosed with a ﬁrst
primary, invasive lung cancer (ICD 10 C33-C34) in 1998–2006
and registered in one of the eight regional English cancer registries
were identiﬁed. The Ofﬁce for National Statistics provides infor-
mation on each patient’s vital status (alive, dead, emigrated or lost
to follow-up) and their postcode of residence at diagnosis, from
which patients were assigned to one of ﬁve deprivation categories
(from 1 most afﬂuent to 5 most deprived) using their postcode of
residence at diagnosis. Only ecological measures of deprivation
derived from the socioeconomic characteristics of the Lower
Super-Output Area (LSOA) in which each patient was resident at
the time of diagnosis, but not individual-level information, were
available. Deprivation categories were deﬁned from the income
domain score of the IMD (2004)24 using administrative data for
the 34 378 LSOAs in England.
Each cancer record was linked to an extract of the Hospital
Episode Statistics (HES)25 database from 1998 to 2006 using
NHS number, sex, date of birth and postcode at time of diagno-
sis. Cancer registry data were available for patients diagnosed
up to the end of 2009 and followed up to the end of 2010.
Data for HES episodes were only available up to the end of
2006, and therefore it was decided to restrict the analysis to the
patients diagnosed in 1998–2006. The ﬁrst curative surgical
procedure was identiﬁed from each linked patient record and
was considered for analysis if it included OPCS-4 episode pro-
cedure codes (Ofﬁce of Population Census and Surveys
Classiﬁcation of Surgical Operations and Procedures-4) of exci-
sion of lesion of trachea (E391, E398, E399), excision of carina
(E441), resection of bronchus and anastomosis (E461), total
pneumonectomy (E541), bilobectomy (E542), lobectomy
(E543), excision of lung segment (E544), partial lobectomy
(E545), excision of lung (E548) E549), excision of lung
unspeciﬁed (E549), excision of lesion of lung (E552, 559), exci-
sion of lesion of chest wall (ET013) and insertion of prosthesis
into chest wall NEC (ET023). If the patient received two of the
listed curative operations in different episodes, the ﬁrst oper-
ation was considered.
Cancer registry data include the date of diagnosis for each
patient. The linkage of cancer records to HES allows the extract
of all treatments that patients were recorded to have received
between 1998 and 2006. It is possible that the treatment infor-
mation in the HES extract is for a primary tumour prior to the
one under study. For example, if a patient had a primary tumour
in 1997 and a second primary in 2005, it is possible that the
linkage process would result in analysing the treatment for the
cancer in 1997 similar to that of the treatment for the cancer in
2005. To avoid this, only patients who underwent a surgical pro-
cedure between 1 month before and 6 months after cancer diag-
nosis were considered as treated by surgery.
Information on PCTs’ spending on cancer was extracted from
the 2008–2009 Cancer Networks Workbook 1.1. This enables
PCTs to compare spending on cancer within their geographic
areas with that of other PCTs. Information on spending on lung
cancer was collated from the NHS National Programme Budget
Project (NPBP). This project aims to identify expenditure on 23
programmes of care including infectious diseases, cancer and
mental health problems. Data on PCT spending by cancer site
were available only for the years 2006/2007, 2007/2008 and
2008/2009, and show that spending on cancer varied for a
number of PCTs from year to year.26 There is some indication
that PCTs with low spending in 1 year tend to have increased
spending in the following year.
Statistical analysis
We ﬁtted mixed effect logistic models to predict surgical treat-
ment within 6 months after diagnosis (model 1) and mortality
within 1 year of diagnosis (model 2). Multilevel models are
designed for data grouped in clusters or hierarchies, with a single
dependent variable at the lowest level and explanatory variables
at each level of the hierarchy. With these models, we can evaluate
how much of the variability of the dependent variable is attribu-
ted to the patients and how much is attributed to PCTs.
To better understand hierarchical models, let us assume that a
total of n patients (level 1) are nested within J PCTs (level 2),
with ni patients in PCTj. By yij, we denote the response of
patient i in PCTj, where the response is either death or surgery
(referred to respectively as models 1 and 2) (within the deﬁned
period). Assuming
yij  Binomialð1;pijÞ ð1Þ
Logit(pij) ¼ log pij1 pij
 
¼ b0 þ b1x1ij þ b2x2ij þ    þ bpxpij þ uj þ 1ij ð2Þ
with 1ijjx1ij; x2ij; . . . ; xpij; uj  N(0;s21Þ; ujjx1ij; x2ij; . . . ; xpij 
N(0;s2uÞ; uj independent across PCTs and εij are independent
across both PCTs and patients, and xkij representing the value of
explanatory variable Xk for patient i in PCT j.
27
The relationships between each of the two outcomes (on the
log-odds scale) and two of the explanatory variables, age at diag-
nosis and year of diagnosis, are expected to be non-linear. For
this reason, their effect is modelled using cubic splines, a set of
piecewise polynomials of order 3 that are joined together to
deﬁne a smooth curve.28 29 The additional predictors in both
models were sex and deprivation index. In these random inter-
cept models, variations across PCTs are captured by the random
component uj, which represents a PCT’s departure from the
mean log odds of PCTs.
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To understand the impact of surgery on mortality within
1 year, model 2 was extended to include curative surgery within
the window of 1 month before and up to 6 months after diagno-
sis (model 3).
We then examined whether the average amount spent on lung
cancer could additionally explain the variation across PCTs. The
average spending in pounds per 1000 patients for the three avail-
able years (2006/2007, 2007/2008 and 2008/2009) was included
in model 2 as a proxy for spending during the full follow-up
period (model 4). This average was grouped in four categories
(<£3500, £3500–£4499, £4500–£5499, >£5000 thousand).
The predicted PCT-speciﬁc random intercepts derived from
ﬁtting the four mixed-effects models were used to visually identify
PCTs with below-average curative surgery rates and those with
above-average mortality from NSCLC, having accounted for the
model-speciﬁc predictors using caterpillar plots. However, this
approach does not adequately account for the variability of the esti-
mates within each PCT. An alternative is to use funnel plots which
have been advised for institutional comparisons of performance.30
Funnel plots have been widely used in meta-analysis to detect publi-
cation bias. They also became more popular recently in visualising
performance indicators such as risk rates and relative survival esti-
mates.30–32 Estimates are plotted with three superimposed lines, a
‘target’, or reference, quantity and upper and lower ‘control limits’,
beyond which the estimate is considered an ‘outlier’. The control
limits are calculated from a function of the statistical precision of
the estimates. This gives the control limits the shape of the funnel
with the wider part reﬂecting increased variability from less precise
estimates. Funnel plots were therefore used to visually inspect the
predicted PCT-speciﬁc random intercepts derived from each of the
four mixed effect regression models, against their associated preci-
sion, given by the inverse of their variance. The target line was set
at zero, because the expected value of the random intercept is zero
(uj  Nð0;s2uÞ), while the upper and lower limits were two
SDs above and below this target line.
RESULTS
Descriptive
A total of 228 247 patients were diagnosed with NSCLC during
1998–2006, and of these, 192 658 (84%) were identiﬁed within
the extract of the HES database. The percentage of successful
linkage with HES improved from 77% in 1998 to 86% in 2005.
One record was excluded because of a missing postcode. A ﬁnal
data set of 192 657 records of patients diagnosed with NSCLC
between 1998 and 2006 and followed up to 2010 and linked to
HES episodes was analysed. The characteristics of these patients
are detailed in table 1.
Over 40% of the patients were older than 75 years of age;
61% were men and 26% were from the most deprived socio-
economic category. The unadjusted rate of death within the ﬁrst
year after diagnosis decreased slightly throughout the study
period from 75% in 1998 to 73% in 2006; it was slightly higher
among men and highest in the oldest age group (81%). Around
10% of the patients received curative surgery within the time
window of 1 month before and up to 6 months after being diag-
nosed with cancer, and this percentage was almost unchanged
throughout the study period.
The results of ﬁtting the random intercept models for the
odds of curative surgery and odds of 1-year mortality are
reported in terms of ORs (table 2).
Table 1 Number (%) of patients with lung cancer by surgical treatment and mortality within 1 year
N
Patients treated by surgery Death within 1 year
N Per cent N Per cent
All patients 192 657 19 153 9.94 142 023 73.72
Year of diagnosis
1998 18 887 1883 9.97 14 244 75.42
1999 20 541 1961 9.55 15 589 75.89
2000 20 981 2133 10.17 15 502 73.89
2001 21 527 2203 10.23 15 922 73.96
2002 21 595 2168 10.04 15 846 73.38
2003 21 527 2138 9.93 15 749 73.16
2004 22 168 2091 9.43 16 162 72.91
2005 22 526 2232 9.91 16 311 72.41
2006 22 905 2344 10.23 16 698 72.90
Age (years)
15–44 2540 515 20.28 1450 57.09
45–54 11 935 1855 15.54 7725 64.73
55–64 35 512 5358 15.09 23 533 66.27
65–74 64 784 7825 12.08 46 399 71.62
75–99 77 886 3600 4.62 62 916 80.78
Deprivation
Most affluent 25 013 2694 10.77 17 950 71.76
2 31 796 3279 10.31 23 370 73.50
3 37 473 3772 10.07 27 501 73.39
4 46 605 4450 9.55 34 647 74.34
Most deprived 51 770 4958 9.58 38 555 74.47
Sex
Male 117 966 11 601 9.83 87 865 74.48
Female 74 691 7552 10.11 54 158 72.51
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Surgery
A very strong and signiﬁcant trend in the odds of surgery was
found in relation to the deprivation index, with patients from
deprived areas having a 27% lower likelihood of having
surgery compared with afﬂuent patients, controlling for sex,
age and year of diagnosis (table 2). A clear trend by age group
was seen in the proportion undergoing surgery. Younger
patients were more likely to be treated by surgery, where the
odds of having surgery were more than three times higher for
those diagnosed at 20 years, and more than twice as high for
patients diagnosed at the age of 30 years compared with
patients diagnosed at the age of 71 years (mean age of diagno-
sis), again controlling for the other variables in the model
(table 2). There was a very slight increase in the adjusted odds
of surgery between 1998 and 2006. Figure 1 provides strong
evidence of geographic differences in treatment by curative
surgery across different PCTs. A total of 32 PCTs were below
the lower control limit (indicated by red dots). The residual
variance of the predicted PCT-speciﬁc random intercepts of
surgery (model 1) was 0.09.
Table 2 Hierarchical random intercept logistic regression models with curative surgery (model 1) and mortality (model 2, model 3, model 4) as
an outcome, random effects for PCTs adjusted for age, year of diagnosis, sex and deprivation
Model 1 Model 2 Model 3 Model 4
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Level 1: patients
Fixed effects
Age at diagnosis
71 1.00 1.00 1.00 1.00
20 3.30 2.61 4.17 0.37 0.31 0.45 0.49 0.40 0.61 0.37 0.31 0.45
30 2.41 2.09 2.79 0.46 0.41 0.52 0.55 0.48 0.53 0.46 0.41 0.52
40 1.81 1.68 1.96 0.56 0.53 0.59 0.62 0.58 0.66 0.56 0.53 0.59
50 1.43 1.36 1.50 0.68 0.65 0.70 0.71 0.68 0.73 0.68 0.65 0.70
60 1.17 1.13 1.21 0.81 0.79 0.83 0.82 0.80 0.84 0.81 0.79 0.83
80 0.34 0.32 0.36 1.60 1.55 1.65 1.29 1.25 1.33 1.60 1.55 1.65
Year of diagnosis
1998 1.00 1.00 1.00 1.00
1999 1.04 1.02 1.07 0.96 0.94 0.98 0.96 0.95 0.98 0.96 0.94 0.98
2000 1.08 1.03 1.13 0.92 0.89 0.95 0.93 0.90 0.96 0.92 0.89 0.95
2001 1.09 1.03 1.16 0.89 0.85 0.92 0.89 0.86 0.93 0.89 0.85 0.92
2002 1.09 1.03 1.15 0.86 0.83 0.89 0.86 0.83 0.90 0.86 0.83 0.89
2003 1.07 1.02 1.12 0.84 0.81 0.87 0.83 0.80 0.86 0.84 0.81 0.87
2004 1.06 1.01 1.12 0.83 0.80 0.86 0.82 0.79 0.85 0.83 0.80 0.86
2005 1.09 1.04 1.14 0.83 0.80 0.85 0.82 0.79 0.85 0.83 0.80 0.85
2006 1.14 1.07 1.21 0.83 0.79 0.86 0.83 0.79 0.87 0.83 0.79 0.85
Sex
Male 1.00 1.00 1.00 1.00
Female 1.06 1.02 1.09 0.89 0.87 0.91 0.89 0.87 0.91 0.89 0.87 0.91
Deprivation
Most affluent 1.00 1.00 1.00 1.00
2 0.94 0.89 0.99 1.08 1.04 1.13 1.08 1.04 1.12 1.08 1.04 1.13
3 0.91 0.87 0.97 1.08 1.04 1.12 1.06 1.02 1.11 1.08 1.04 1.12
4 0.83 0.78 0.87 1.15 1.11 1.19 1.12 1.07 1.16 1.15 1.11 1.20
Most deprived 0.73 0.69 0.77 1.23 1.18 1.28 1.16 1.11 1.21 1.23
Surgery
No 1.00
Yes 0.07 0.07 0.08
Spending on lung cancer in pounds per 1000 patients
<£3500 1.00
£3500–£4499 0.93 0.87 0.99
£4500–£5499 0.95 0.89 1.01
>£5000 0.94 0.88 1.00
Intercept 0.08 0.08 0.09 3.04 2.90 3.18 4.22 4.01 4.43 3.18 3.00 3.37
Level 2: PCTs
Random effect
Variance 0.09 0.07 0.12 0.02 0.01 0.02 0.02 0.01 0.02 0.02 0.01 0.02
Model 1: Outcome—surgery within 1 month before and 6 months after diagnosis adjusted for covariates.
Model 2: Outcome—mortality within 1 year after diagnosis adjusted for covariates.
Model 3: Model 2, adjusted for surgery (patient level).
Model 4: Model 2, adjusted for spending on lung cancer (PCT level) per 1000 patients.
PCT, Primary Care Trust.
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Mortality within 1 year after diagnosis
Diagnosis of NSCLC at older ages is associated with higher odds
of death, controlling for year of diagnosis, sex and deprivation
index (table 2, model 2). Patients diagnosed at the age of 40
have almost half of the odds of death compared to those diag-
nosed at the age of 71 (mean age of diagnosis). Women experi-
enced 11% lower odds of death in the ﬁrst year after diagnosis
compared to men, controlling for covariates. The results show a
clear trend of the effect of deprivation index on mortality, with
the most deprived patients having 23% higher odds of death
compared to the most afﬂuent patients, controlling for the other
factors. The odds of death also declined slightly with later years
of diagnosis. The residual variance of the predicted PCT-speciﬁc
random intercepts was 0.02, smaller than that for surgery
(model 2). A likelihood-ratio test comparing the model with a
standard logistic regression model was highly signiﬁcant (likeli-
hood ratio test=1466.50; p<0.001).
The mixed effects model of mortality was further extended
to control for curative surgery (model 3). The OR of death
within the ﬁrst year in patients treated by curative surgery
was very small (0.07), relative to patients who did not undergo
surgery, controlling for the other factors in the model (model 3).
This implies that not receiving surgery is associated with
more than 14 times the odds of death compared to those who
receive surgery, controlling for covariates. However, the
effects of age, year, sex and deprivation on mortality within
1 year barely changed after adjusting for surgery (model 3)
(table 2, model 4).
Figure 2 shows some evidence of geographical differences in
the predicted PCT-speciﬁc random intercepts for mortality. PCTs
identiﬁed in ﬁgure 1 as having a below-average uptake of surgery
are identiﬁed in this ﬁgure in red. A total of 22 (69%) of 32 PCTs
that were below the lower control limit of surgery have predicted
random intercepts for mortality above zero, and 13 (40%) were
above the upper control limit of mortality within 1 year (ﬁgure 2,
model 2). Adjusting for surgery (model 3) explained some of this
variation, highlighting the inverse association between undergoing
surgery and mortality. Additionally, controlling for variation in
spending across PCTs seemed to push some of the PCTs to have
more extreme values (ﬁgure 2, model 4).
DISCUSSION
The results of this study indicate substantial geographical variation
in the use of curative surgical resection and in mortality within
1 year for patients with NSCLC at the level of PCTs in England.
These clear geographical disparities remained after adjusting for
age at diagnosis, sex and socioeconomic deprivation.
Strong inverse relationships were found between the use of
curative surgical treatment and both increasing age at diagnosis
and deprivation, while short-term mortality also increased with
increasing age and deprivation. This excess mortality reduced
dramatically, in particular among the oldest group of patients
after accounting for their lower proportion of surgical treatment.
After adjusting for sociodemographic factors, the use of surgical
treatment with curative intent increased regularly with a calendar
year, while mortality decreased. However, at the national level,
only a tenth of the patients diagnosed with NSCLC in 2006
received such surgical treatment.
Only one study investigated the variation in surgical treatment
and mortality at the PCT level for the whole of England.4 They
also found wide variation in surgical treatment between PCTs,
and a strong inverse association between surgery treatment and
mortality.13 However, these results did not account for the hier-
archical structure of the data, that is, for the higher similarity
(in particular for healthcare management) between patients
within a given PCT than between those from different PCTs. We
hypothesised that the PCTs that were below the lower control
limit for surgery would be the ones with above-average mortality
using funnel plots. Variation in mortality within the ﬁrst year
after diagnosis was also apparent by PCTs. Most of the PCTs that
were below the lower limit for surgery were above average for
mortality within 1 year, and 38% were above the upper control
limit of mortality. We had clear evidence that surgical treatment
explained some of the variation (model 3, ﬁgure 2) that was due
to mortality after the adjustment of predictors.
The average rate of surgical treatment of the patients with
NSCLC diagnosed during 1998–2006 in the linked records of
cancer registry and the HES was almost 10%, which is lower
than the reported rates in equally developed European countries,
such as 24% for Italy33 and 18% for Sweden.34 The reasons for
this are likely to be multifactorial and include a lower number of
specialist thoracic surgeons35 and higher rates of comorbidities33
in the UK. Delays from ﬁrst referral for diagnosis to assessment
for surgery have also been suggested to be a factor.36
A clear trend in rates across deprivation categories was identi-
ﬁed, where patients resident in deprived areas were less likely to
undergo curative surgery, and more likely to die within 1 year
after diagnosis. Our ﬁndings have already been supported by
similar studies on the impact of age on treatment and mortality
for patients with NSCLC7 and socioeconomic deprivation.37–39
PCTs are responsible for the management, planning and
funding of healthcare in a small deﬁned geographical area and
therefore management of hospitals and treatment provided in
their local territories. Until 2013, PCTs were responsible for
80% of the total NHS budget. We used hierarchical models to
evaluate how much of the variability of the surgical treatment
and mortality was attributed to the patients, and how much was
attributed to PCTs, after adjusting for known predictors. We
expect that much of the unexplained variability of mortality
would be due to factors at the PCT level. The NHS implemented
the NPBP in 2002 to monitor where NHS resources are invested.
PCTs were asked to declare the proportion of their budget spent
on major diseases including cancer. Information on overall
spending on cancer at the PCT level was available only for
Figure 1 Funnel plot of predicted random intercepts of treatment by
curative surgery within 1 year after diagnosis for patients with NSCLC
(15–99 years) diagnosed during 1998–2006 in England. The target is
ﬁxed as zero, which speciﬁes the expected value of the random effect.
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3 years from the NPBP. The average spending of the available
3 years was considered as an indication of spending over all the
periods considered in this paper. The variability in mortality
1 year after diagnosis was not explained by the spending on lung
cancer at the PCT level after controlling for other covariates at
the patient level such as age, sex, deprivation and year of diagno-
sis. However, NPBP data have many limitations. The large vari-
ation in spending between PCTs suggests that the recorded
spending of a considerable number of PCTs might have been
inaccurate, especially in the early years when this programme
was ﬁrst implemented.26
The main strength of this study is the large national
population-based cancer registry data analysis, which comprises
complete cancer registration linked to high-quality information
on treatment extracted from HES. The analysis accounted for
the hierarchical structure of the data, with patients at the ﬁrst
level and PCTs at the second level. The mixed-effects models
account for clustering and take into account the dependence of
outcomes within a cluster, the PCT in our case. We show that
funnel plots originally used for the comparisons of hospital-
based estimates30 could also be used to identify outliers of
random effects predicted by mixed effect models. This latter
use helps to identify geographical variation in measures such as
mortality and surgical treatment in population-based cancer
data.
The major limitation, however, is the absence of information on
well-known strong predictors of surgical treatment and mortality at
the PCT level, such as stage at diagnosis, comorbidities,40 special-
isation of the surgeon41 42 and hospital volumes.43 Characteristics
of the hospital at which the patient underwent surgery play an
important role in the patients’ well-being after surgery. The patients
with NSCLC ﬁrst seen in a thoracic surgical centre were more
likely to have surgery than those seen in non-surgical centres,44 and
better survival outcomes have been demonstrated for centres with
higher volumes of surgical procedures.45 We do not expect much
change in spending on cancer allocated by PCTs within a range of
10 years;26 however, a more accurate measure on spending for the
equivalent year of the cancer diagnosis of patients included in the
study would have led to more accurate results.
Our main results suggest the presence of clear variation in the
use of surgical treatment of NSCLC and mortality. Mixed-effects
models combined with the funnel plot approach were useful for
assessing disparities and assessing the PCTs that were above average
in mortality and below average in surgery. It is clear that patients
Figure 2 Funnel plots of predicted random intercepts of mortality within 1 year of diagnosis, controlling for (A) covariates (age, year of diagnosis,
sex and deprivation) (model 2), (B) covariates and treatment by curative surgery (model 3), (C) covariates and spending on lung cancer at Primary
Care Trust level (model 4) for patients with non-small cell lung cancer (15–99 years) diagnosed during 1998–2006 in England. The target is ﬁxed as
zero, which speciﬁes the expected value of the random effect.
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managed by PCTs with lower rates of surgical resection experience
higher rates of mortality within 1 year after the diagnosis of
NSCLC. To explain the variations in treatment and mortality that
we have demonstrated, a range of other factors will need to be ana-
lysed in future studies, including geographical differences in
waiting times from referral to surgery, stage at diagnosis, access to
other non-surgical treatments and the nature of local multidisciplin-
ary teams—especially the level of involvement of specialist thoracic
surgeons. The conﬁguration of the NHS in England is changing
rapidly at the time of writing, and our work accordingly will need
to be updated shortly. More accurate data on costs and expenditure
might be expected from this current reorganisation, which may
make it possible to more accurately examine the relationship
between expenditure and outcomes in this common disease.
What is already known on this subject?
Non-small cell lung cancer comprises approximately 85% of all
lung cancer cases, and surgery is the preferred treatment for
patients. The National Health Service established Primary Care
Trusts (PCTs) in 2002 to manage local health needs.
What this study adds?
Older deprived patients and those who did not receive surgery had
much higher odds of death 1 year after being diagnosed with lung
cancer. Mixed-effects models combined with the funnel plot
approach were useful for assessing the performance of PCTs that
were above average in mortality and below average in surgery.
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